The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The gene symbol C28G1.2 is not safely interchangeable with any named srp gene in the literature. Based on the supplied UniProt metadata, Q18287 is a Caenorhabditis elegans protein encoded by ORF C28G1.2/CELE_C28G1.2 and containing a serpin-family domain. This identity, organism, and domain assignment are internally consistent. However, searches for the exact identifiers “C28G1.2” and “Q18287” found no publication that directly characterizes this protein or maps it authoritatively to SRP-1, SRP-2, SRP-3, SRP-6, or SRP-7.
Accordingly, the defensible primary annotation is:
Serpin domain-containing protein of unknown molecular function. A role in protease regulation is plausible but unproven; inhibitory activity, protease target, substrate specificity, localization, expression pattern, biological pathway, and organismal phenotype remain unknown.
This is an important negative result. In particular, biochemical and muscle-localization findings for SRP-3, and intestinal/hypodermal findings for SRP-2, must not be assigned to Q18287 without an authoritative identifier cross-reference. The retrieved papers do not provide such a cross-reference. (pak2006thecaenorhabditiselegans pages 1-2, pak2006thecaenorhabditiselegans pages 5-6, whisstock1999serpinsinthe pages 3-4, whisstock1999serpinsinthe pages 1-3)
| Question | Conclusion | Evidence level | Key caveat |
|---|---|---|---|
| Identity and organism | C28G1.2 / CELE_C28G1.2, UniProt Q18287, from Caenorhabditis elegans, matches the target specified in the user-supplied UniProt metadata. | User-supplied database metadata | Retrieved literature does not independently connect Q18287/C28G1.2 to a characterized, named srp gene. |
| Domain and family | The supplied metadata assigns Serpin_dom (IPR023796), serpin-superfamily annotations (IPR036186; IPR042185), and Pfam Serpin (PF00079), supporting classification as a serpin-domain-containing protein. Historical genome analysis confirms that structurally diverse serpin-like proteins occur in C. elegans (whisstock1999serpinsinthe pages 1-3, whisstock1999serpinsinthe pages 3-4). | Strong domain-level inference | A serpin fold does not establish protease-inhibitory activity; non-inhibitory, truncated, and structurally divergent serpins exist. |
| Exact-gene biochemical function | Unknown. Exact-identifier searches found no paper directly characterizing C28G1.2/Q18287. | No direct evidence located | Biochemical results for other worm serpins cannot be transferred to this protein. |
| Target or substrate specificity | Unknown. No target protease, cleavage sequence, reaction, inhibition constant, stoichiometry, or physiological substrate was found for the exact protein. | No direct evidence located | Inhibitory serpins can use a reactive-center loop as bait and trap a protease after cleavage, but this is only a family-level mechanism (chan2024theinhibitionof pages 1-2, fluhr2012serpinproteaseinhibitors pages 1-2). Specificity can also depend on exosites (garrigues2024molecularinsightsinto pages 79-83, garrigues2024molecularinsightsinto pages 83-87). |
| Cellular or extracellular localization | Unknown. No direct signal-peptide, trafficking, microscopy, fractionation, or secretion evidence was found for Q18287. | No direct evidence located | Localization of other intracellular C. elegans serpins must not be assumed for C28G1.2 (pak2006thecaenorhabditiselegans pages 1-2, silverman2015theaggregationproneintracellular pages 3-5). |
| Expression, phenotype, and pathway | Unknown. No exact-gene expression pattern, mutant or RNAi phenotype, genetic interaction, or signaling/biochemical pathway was identified. | No direct evidence located | SRP-3 muscle expression and protease inhibition concern a different named serpin (pak2006thecaenorhabditiselegans pages 5-6, pak2006thecaenorhabditiselegans pages 1-2). Neither SRP-3 nor SRP-2 should be mapped to Q18287 without an authoritative cross-reference. |
| Recent 2023–2024 evidence | No 2023–2024 exact-gene publication was found. Recent family-level research emphasizes serpin conformational complexity and shows that AlphaFold or molecular-dynamics predictions can miss functionally important alternative states (garridorodriguez2024analysisofalphafold pages 1-2, garridorodriguez2024analysisofalphafold pages 17-18). | Current family-level evidence; no exact-gene evidence | A predicted native serpin-like structure would not prove inhibition, conformational switching, localization, or specificity. |
| Safest functional annotation | Serpin domain-containing protein of unknown molecular function. Protease regulation is a testable hypothesis, but inhibitory status, target, localization, and pathway should remain unassigned. | Conservative annotation supported by domain metadata | The canonical serpin inhibitory mechanism is family-level inference only; do not transfer SRP-2 or SRP-3 functions to Q18287. |
Table: Evidence assessment for C. elegans C28G1.2/Q18287, separating user-supplied domain metadata from exact-gene experimental evidence and serpin-family inference. It highlights the major unresolved functional-annotation questions and prevents conflation with SRP-2 or SRP-3.
Thus, the requested gene symbol matches the supplied protein record and organism. The domain calls also agree with the protein description. What cannot be verified from the retrieved literature is a mapping from C28G1.2/Q18287 to any experimentally characterized named worm serpin.
Historical papers use names such as SRP-2 and SRP-3, whereas the target is supplied as C28G1.2/Q18287. The SRP-3 study reports no C28G1.2 or Q18287 identifier in the retrieved text. Therefore, under the user’s required safeguard, that study is evidence about a different or at least not demonstrably identical protein and cannot establish Q18287 function. (pak2006thecaenorhabditiselegans pages 1-2, pak2006thecaenorhabditiselegans pages 5-6)
Beyond the supplied database-level domain annotation, no exact-gene experimental evidence was located. Specifically, the search found no Q18287/C28G1.2 study reporting:
Consequently, there is no established reaction to report. Serpins are generally inhibitors or non-catalytic binding proteins rather than enzymes that repeatedly catalyze substrate turnover. Even the statement “Q18287 is a protease inhibitor” would presently exceed the evidence.
Canonical serpins share a fold built from approximately three β-sheets and seven to nine α-helices, with a solvent-exposed reactive-center loop (RCL). Historical C. elegans analysis described the conserved architecture as nine α-helices and three β-sheets. (garridorodriguez2024analysisofalphafold pages 1-2, whisstock1999serpinsinthe pages 1-3)
In an inhibitory serpin, the RCL acts as a bait substrate. A target protease binds and cleaves the P1–P1′ bond, generating an acyl-enzyme intermediate. Rapid insertion of the cleaved loop into β-sheet A then translocates and distorts the covalently attached protease, trapping it in an effectively irreversible complex. If loop insertion loses the kinetic competition with protease de-acylation, the serpin can instead behave as an ordinary cleavable substrate. (chan2024theinhibitionof pages 1-2, fluhr2012serpinproteaseinhibitors pages 1-2)
This mechanism explains why a serpin is not normally assigned a conventional catalytic reaction: an inhibitory molecule is generally consumed with its target in a suicide-substrate-like event.
Not all serpin-fold proteins inhibit proteases. Some are non-inhibitory, truncated, latent, polymerized, or adapted to other binding functions. The 1999 C. elegans genome survey found proteins ranging from apparently complete serpins to sequences with extensive deletions or principally the C-terminal serpin core. Its authors explicitly warned that an inhibitory-loop-like sequence was a prediction, not direct evidence of inhibition. (whisstock1999serpinsinthe pages 3-4, whisstock1999serpinsinthe pages 1-3)
The safest interpretation is therefore:
For inhibitory serpins, residues around the RCL scissile bond are important determinants of target preference, but modern structural analysis shows that exosite contacts outside the RCL can contribute substantially to recognition. In one recent structurally characterized serpin–protease system, more than 40% of contacts occurred outside the RCL. Thus, even a confidently predicted P1 residue would not by itself establish Q18287 specificity. (garrigues2024molecularinsightsinto pages 79-83, garrigues2024molecularinsightsinto pages 83-87)
Whisstock and colleagues’ genome survey, published July 1999, initially identified eight strongly serpin-like C. elegans sequences and ultimately recovered 12 candidate sequences through iterative searches. These included apparently complete candidates as well as partial or structurally divergent sequences. Five candidates in the tabulated subset had predicted inhibitory-loop signatures, but the authors stressed that none was thereby proven to inhibit a protease. DOI: https://doi.org/10.1002/(SICI)1097-0134(19990701)36:1%3C31::AID-PROT3%3E3.0.CO;2-Q. (whisstock1999serpinsinthe pages 3-4, whisstock1999serpinsinthe pages 1-3)
A later experimental paper, published 21 March 2006, described nine transcribed intracellular-serpin genes, of which five—srp-1, srp-2, srp-3, srp-6, and srp-7—were computationally predicted to encode full-length inhibitory-type proteins. These counts differ from the earlier survey because the studies applied different sequence and transcript criteria. Neither count establishes which historical candidate corresponds to C28G1.2/Q18287. DOI: https://doi.org/10.1021/bi052626d. (pak2006thecaenorhabditiselegans pages 5-6, pak2006thecaenorhabditiselegans pages 1-2)
SRP-3 was cloned and biochemically shown to inhibit chymotrypsin and cathepsin G, but not elastase-like enzymes. Reporter constructs indicated expression mainly in anterior body-wall muscle across postembryonic development. The authors proposed a possible role in muscle homeostasis, but did not establish an in-vivo physiological target or loss-of-function pathway. These are valuable examples of the experiments needed for Q18287, not transferable functional annotations. (pak2006thecaenorhabditiselegans pages 5-6, pak2006thecaenorhabditiselegans pages 1-2)
Likewise, the same literature describes SRP-2 as a cross-class inhibitor of granzyme-B-like serine proteases and papain-like cysteine proteases, expressed in hypodermal and intestinal cells. Because no retrieved source identifies SRP-2 as C28G1.2/Q18287, these properties must not be assigned to the target. (pak2006thecaenorhabditiselegans pages 1-2, silverman2015theaggregationproneintracellular pages 3-5)
These comparator studies also demonstrate an expert consensus particularly relevant here: serpin activity has to be measured experimentally rather than inferred from alignment alone. (pak2006thecaenorhabditiselegans pages 5-6)
No defensible cellular or extracellular localization can presently be assigned. A serpin domain does not indicate whether a protein is secreted, cytosolic, nucleocytosolic, organellar, or membrane-associated. Intracellular clade-B-like serpins often lack classical cleavable signal peptides, but that family tendency is not exact evidence for Q18287. (pak2006thecaenorhabditiselegans pages 1-2, silverman2015theaggregationproneintracellular pages 3-5)
A localization claim would require, at minimum, analysis of the exact Q18287 sequence for a signal peptide and transmembrane segments, followed by endogenous tagging, microscopy, and biochemical fractionation. Signal prediction alone would remain provisional.
No signaling or biochemical pathway containing C28G1.2 was identified. Protease-control pathways are plausible at the superfamily level, but it would be speculative to assign Q18287 to muscle maintenance, apoptosis, lysosomal regulation, innate immunity, reproduction, stress responses, or any named kinase cascade. Such roles are documented or proposed for other serpins, not this protein.
No 2023–2024 publication directly concerning C28G1.2/Q18287 was found. The most relevant recent advance is methodological: serpin function remains unusually difficult to infer from static structural models because native inhibitory states are metastable and function depends on large conformational transitions.
A PLOS ONE study published 5 July 2024 tested AlphaFold and molecular-dynamics predictions against five experimentally supported antithrombin folding-defect variants selected from 350 unrelated patients. AlphaFold generated native-like structures for all variants regardless of their known in-vivo conformational effects, and simulations extending to 1,000 ns did not reproduce the relevant transitions. The authors concluded that better prediction strategies are needed for conformationally sensitive serpins. DOI: https://doi.org/10.1371/journal.pone.0304451. This result strongly cautions against treating a native-looking Q18287 structure prediction as evidence of inhibitory function. (garridorodriguez2024analysisofalphafold pages 1-2, garridorodriguez2024analysisofalphafold pages 17-18)
A review published 2 February 2024 reiterated the irreversible conformational “molecular mousetrap” mechanism and discussed how cofactors can allosterically augment selected serpin–protease interactions. DOI: https://doi.org/10.3390/ijms25031804. These developments refine family-level understanding but do not identify a cofactor or target for Q18287. (chan2024theinhibitionof pages 1-2)
A broader review published 5 November 2024 summarized the clinical importance of serine-protease regulation and noted that approximately one-third of known human proteases are serine proteases. DOI: https://doi.org/10.3390/catal14110787. This statistic illustrates the broad translational relevance of protease inhibition, but it is not evidence for a biomedical role of the worm protein. (wei2024advancementsinserine pages 1-2)
There is no current real-world implementation specific to C28G1.2/Q18287—no reported diagnostic, therapeutic, biotechnology reagent, validated screening target, or engineered inhibitor was found.
At the family level, characterized serpins regulate coagulation, fibrinolysis, complement, and inflammation; engineered RCLs and exosite interfaces are being explored to redirect protease specificity. Clinically used or investigated human serpins demonstrate that the fold can be pharmacologically important, but transfer of those applications to an uncharacterized nematode protein would be premature. (wei2024advancementsinserine pages 1-2, garrigues2024molecularinsightsinto pages 79-83, garrigues2024molecularinsightsinto pages 83-87)
The immediate practical value of Q18287 is therefore as a functional-genomics target: it could help define how divergent nematode serpin-domain proteins evolved and whether they are inhibitory, non-inhibitory, or structurally specialized.
The highest-value studies would be:
srp synonym using genomic coordinates and exact sequence identity.For databases or downstream analyses, use:
C28G1.2 / Q18287 — serpin domain-containing protein; molecular function, target specificity, cellular localization, biological process, and pathway unknown.
Do not annotate it as chymotrypsin inhibitor, cathepsin inhibitor, muscle serpin, intracellular serpin, secreted serpin, or member of a specific signaling pathway without first establishing an exact identifier mapping and obtaining direct biochemical or genetic evidence.
References
(pak2006thecaenorhabditiselegans pages 1-2): Stephen C. Pak, Christopher Tsu, Cliff J. Luke, Yuko S. Askew, and Gary A. Silverman. The caenorhabditis elegans muscle specific serpin, srp-3, neutralizes chymotrypsin-like serine peptidases. Biochemistry, 45 14:4474-80, Apr 2006. URL: https://doi.org/10.1021/bi052626d, doi:10.1021/bi052626d. This article has 16 citations and is from a peer-reviewed journal.
(pak2006thecaenorhabditiselegans pages 5-6): Stephen C. Pak, Christopher Tsu, Cliff J. Luke, Yuko S. Askew, and Gary A. Silverman. The caenorhabditis elegans muscle specific serpin, srp-3, neutralizes chymotrypsin-like serine peptidases. Biochemistry, 45 14:4474-80, Apr 2006. URL: https://doi.org/10.1021/bi052626d, doi:10.1021/bi052626d. This article has 16 citations and is from a peer-reviewed journal.
(whisstock1999serpinsinthe pages 3-4): James C. Whisstock, James A. Irving, Stephen P. Bottomley, Robert N. Pike, and Arthur M. Lesk. Serpins in the caenorhabditis elegans genome. Proteins: Structure, 36:31-41, Jul 1999. URL: https://doi.org/10.1002/(sici)1097-0134(19990701)36:1<31::aid-prot3>3.0.co;2-q, doi:10.1002/(sici)1097-0134(19990701)36:1<31::aid-prot3>3.0.co;2-q. This article has 27 citations.
(whisstock1999serpinsinthe pages 1-3): James C. Whisstock, James A. Irving, Stephen P. Bottomley, Robert N. Pike, and Arthur M. Lesk. Serpins in the caenorhabditis elegans genome. Proteins: Structure, 36:31-41, Jul 1999. URL: https://doi.org/10.1002/(sici)1097-0134(19990701)36:1<31::aid-prot3>3.0.co;2-q, doi:10.1002/(sici)1097-0134(19990701)36:1<31::aid-prot3>3.0.co;2-q. This article has 27 citations.
(chan2024theinhibitionof pages 1-2): Edward D. Chan, Paul T. King, Xiyuan Bai, Allen M. Schoffstall, Robert A. Sandhaus, and Ashley M. Buckle. The inhibition of serine proteases by serpins is augmented by negatively charged heparin: a concise review of some clinically relevant interactions. Feb 2024. URL: https://doi.org/10.3390/ijms25031804, doi:10.3390/ijms25031804. This article has 16 citations.
(fluhr2012serpinproteaseinhibitors pages 1-2): Robert Fluhr, Nardy Lampl, and Thomas H. Roberts. Serpin protease inhibitors in plant biology. Physiologia plantarum, 145 1:95-102, May 2012. URL: https://doi.org/10.1111/j.1399-3054.2011.01540.x, doi:10.1111/j.1399-3054.2011.01540.x. This article has 77 citations and is from a peer-reviewed journal.
(garrigues2024molecularinsightsinto pages 79-83): RJ Garrigues. Molecular insights into the regulation of complement protease c1s by the multi-specific serpin c1 esterase inhibitor. Unknown journal, 2024.
(garrigues2024molecularinsightsinto pages 83-87): RJ Garrigues. Molecular insights into the regulation of complement protease c1s by the multi-specific serpin c1 esterase inhibitor. Unknown journal, 2024.
(silverman2015theaggregationproneintracellular pages 3-5): Richard M Silverman, Erin E Cummings, Linda P O’Reilly, Mark T Miedel, Gary A Silverman, Cliff J Luke, David H Perlmutter, and Stephen C Pak. The aggregation-prone intracellular serpin srp-2 fails to transit the er in caenorhabditis elegans. Genetics, 200:207-219, Mar 2015. URL: https://doi.org/10.1534/genetics.115.176180, doi:10.1534/genetics.115.176180. This article has 3 citations and is from a domain leading peer-reviewed journal.
(garridorodriguez2024analysisofalphafold pages 1-2): Pedro Garrido-Rodríguez, Miguel Carmena-Bargueño, María Eugenia de la Morena-Barrio, Carlos Bravo-Pérez, Belén de la Morena-Barrio, Rosa Cifuentes-Riquelme, María Luisa Lozano, Horacio Pérez-Sánchez, and Javier Corral. Analysis of alphafold and molecular dynamics structure predictions of mutations in serpins. Jul 2024. URL: https://doi.org/10.1371/journal.pone.0304451, doi:10.1371/journal.pone.0304451. This article has 23 citations and is from a peer-reviewed journal.
(garridorodriguez2024analysisofalphafold pages 17-18): Pedro Garrido-Rodríguez, Miguel Carmena-Bargueño, María Eugenia de la Morena-Barrio, Carlos Bravo-Pérez, Belén de la Morena-Barrio, Rosa Cifuentes-Riquelme, María Luisa Lozano, Horacio Pérez-Sánchez, and Javier Corral. Analysis of alphafold and molecular dynamics structure predictions of mutations in serpins. Jul 2024. URL: https://doi.org/10.1371/journal.pone.0304451, doi:10.1371/journal.pone.0304451. This article has 23 citations and is from a peer-reviewed journal.
(wei2024advancementsinserine pages 1-2): Yang Wei, Mingdong Huang, and Longguang Jiang. Advancements in serine protease inhibitors: from mechanistic insights to clinical applications. Catalysts, 14:787, Nov 2024. URL: https://doi.org/10.3390/catal14110787, doi:10.3390/catal14110787. This article has 35 citations.